Stewart Richard Alistair 4

What Happened

• Stewart Richard Alistair, CEO of Achieve Life Sciences (ACHV), was granted a derivative equity award covering 645,000 shares on January 28, 2026. The Form 4 lists the transaction as an award (derivative) with a reported price/value of $0. This was a grant of an equity award (option-style) — not a cash purchase or sale — and does not indicate immediate share ownership or a cash outlay.

Key Details

• Transaction date: January 28, 2026; Form 4 filed January 30, 2026 (filed two days after the grant; appears timely).
• Security/amount: 645,000-share derivative award (option-style grant). Reported price/value on the Form 4: $0.
• Shares owned after transaction: not specified in the summary provided.
• Footnote (vesting): The award vests 1/4 on the first anniversary of January 28, 2026, then in substantially equal monthly installments over 36 months, subject to continued service (see F1).
• No indication in the filing that this was a cashless exercise, sale, gift, or subject to a 10b5-1 plan.

Context

• This was a time-based equity grant (derivative award) that vests over four years; the grant itself is a common form of executive compensation and does not represent an immediate market purchase or sale. Because it’s an unexercised derivative award, there’s no proceeds or realized value reported at grant.